acetylated peptide comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-07-10. Where a claim depends on a specific study, the study is described rather than over-claimed.
Identity and purity are normally assessed by reversed-phase high-performance liquid chromatography, which separates the peptide from related impurities and truncation products. Mass spectrometry confirms molecular mass and detects modifications such as deamidation or oxidation. Amino acid analysis and peptide mapping provide additional sequence-level confirmation. For research material, a certificate of analysis typically reports these results together with water content and counter-ion identity, since the lyophilized powder is often supplied as an acetate or trifluoroacetate salt.
Several factors accelerate degradation: alkaline pH, elevated temperature, exposure to oxidants, and the presence of residual moisture. Deamidation of asparagine residues and oxidation of methionine are the most commonly reported degradation routes. Because the peptide lacks disulfide bonds, it does not undergo the thiol-related aggregation seen in some other biologics, but physical aggregation can still occur at high concentration. Stability data are product-specific, and extrapolating shelf life between formulations is not reliable.
The lyophilized peptide is a white to off-white powder that dissolves freely in water and in aqueous buffers near neutral pH. Because the molecule carries a net negative charge under physiological conditions, saline and phosphate solutions are the usual vehicles, while strongly acidic media are avoided. Stock solutions are commonly divided into small aliquots so that repeated freezing and thawing can be limited, since cycling may encourage aggregation. Solubility in organic solvents is poor and those solvents are seldom used as primary diluents.
Recommended storage for the dry powder is a freezer near minus twenty degrees Celsius, kept desiccated and away from light. Once dissolved, the peptide is less stable and is usually held at two to eight degrees Celsius for short intervals or frozen for longer storage. Stability studies focus on the acetylated terminus and the disulfide linkage because those features define the intact molecule. Common degradation routes include cysteine oxidation, deamidation of asparagine or glutamine side chains, and slow formation of higher-molecular-weight species.
| Property | Value | Notes |
|---|---|---|
| Storage temperature, powder | -20 °C or lower | Protect from light and moisture |
| Storage temperature, reconstituted | 2-8 °C | Use within days |
| Purity testing | Reversed-phase HPLC | Separates truncation products |
| Mass confirmation | Mass spectrometry | Detects deamidation and oxidation |
| Common salt forms | Acetate or trifluoroacetate | Affects solubility and weighing |
Routine handling calls for storage of the lyophilized powder at refrigerated temperatures, away from light, in a sealed container. Working solutions are often prepared in sterile water or buffer and kept cold between uses. Repeated freeze-thaw cycles are generally avoided because they can promote aggregation and loss of material. Laboratories usually record lot number, reconstitution date, and storage conditions so that any change in behavior can be traced to a specific preparation.
Reverse-phase high-performance liquid chromatography is the standard technique for assessing purity and concentration, because the peptide's hydrophobicity allows clean separation from related impurities. Mass spectrometry confirms molecular identity and detects sequence errors or truncations. Amino acid analysis and peptide mapping supply additional structural confirmation when required. Chromatographic purity values reported on certificates of analysis describe the proportion of the main peak and do not by themselves establish biological activity.
Like most short peptides, thymosin alpha-1 is susceptible to hydrolysis under strongly acidic or basic conditions and to oxidation when exposed to air over long periods. The acetylated amino terminus blocks one common degradation route, which contributes to the molecule's relative robustness in solution. Lyophilized material generally retains potency for extended periods when kept cold and dry. Once reconstituted, aqueous solutions are less stable and are typically used within a defined window rather than held indefinitely at ambient temperature.
The compound has been investigated as an adjunct in chronic viral hepatitis and as a vaccine adjuvant, with results that vary by study design and population. Regulators in some countries have approved a synthetic form for specific indications, while other agencies have not. Whether the peptide produces consistent clinical benefit across diverse patient groups is still an open question, and many trials have been small. Its status is therefore best described as investigational in many contexts and established only narrowly.
The name itself causes confusion, because several unrelated thymic peptides share the thymosin label. Thymosin beta-4, for example, is a different molecule with different functions. Naming conventions in the literature also mix descriptive research terms with assigned nonproprietary names, so a reader should confirm which entity a given paper addresses. Clarifying that point is usually the first step in interpreting any claim about this peptide.
Thymosin alpha-1 is a short peptide of 28 amino acid residues first described in the 1970s as a component of thymic extracts. Its N-terminal residue carries an acetyl group, and the sequence is highly conserved across mammalian species. The peptide is not encoded as a standalone gene product; it is released by proteolytic cleavage from the N-terminus of prothymosin alpha, a larger acidic nuclear protein. That precursor relationship places it within a broader family of thymic and immune-associated peptides that have been studied for decades.
Thymosin alpha 1 is a 28-amino-acid peptide first isolated from thymosin fraction 5, a bovine thymic extract. Its sequence begins with an acetylated serine residue and carries a high proportion of acidic residues, so the molecule has a net negative charge near neutral pH. Despite the shared name, it is unrelated in sequence to the thymosin beta family. Synthetic material prepared by solid-phase peptide synthesis is identical in sequence to the natural peptide.
Several names appear in the literature for this peptide, including thymalfasin and the abbreviation T-alpha-1. Naming conventions differ among research articles, regulatory documents, and supplier catalogs, which complicates literature searches. Both synthetic and recombinant production routes yield a peptide with the same 28-residue sequence as the thymic isolate. Because the thymosin label also covers unrelated peptides, sources should be compared by sequence rather than by name alone.
The peptide occurs naturally in thymic tissue and has been detected in serum and other biological fluids. Reported concentrations are low, and reliable measurement generally requires immunoassay or mass spectrometry with an enrichment step. It is released from a larger precursor, prothymosin alpha, by proteolytic cleavage, although the enzymes involved are not fully characterized. Whether circulating levels reflect thymic output specifically remains an open question.
The appointment of the original nine commissioners was intensely followed by the media. Placement firm Spencer Stuart shortlisted a list of potential members and the NRL Partnership whittled it down to the current members. Commissioners were required to not have had any link to any rugby league football governing body or organisation for the previous 2 years to ensure their independence. The inaugural ARL Commissioners were agreed by representatives of the NRL Partnership, the Leagues and the NRL clubs. Future Commissioners are appointed by the Commission itself.
In 1992, Hooters sponsored NASCAR driver Alan Kulwicki as he won the Winston Cup Championship, beating Bill Elliott by ten points, the closest margin in NASCAR prior to The Chase era. On April 1, 1993, Kulwicki, along with several others including Hooters Chairman Bob Brooks's son Mark, were killed in a plane crash near Bristol, Tennessee. They were flying back to the track for Sunday's race after making a sponsor appearance at a Hooters in Knoxville, Tennessee. Hooters remained in the sport, sponsoring drivers like Loy Allen Jr., Rick Mast and Brett Bodine before ending their involvement in 2003. The restaurant returned to NASCAR in 2007 to sponsor a Craftsman Truck Series team led by Jason White, Derrike Cope and Brad Keselowski. Six years later, Hooters sponsored Nationwide Series driver Nelson Piquet Jr.'s car. For the 2016 Bojangles' Southern 500 at Darlington Raceway, Hooters made a comeback in the Cup Series with a one-off paint scheme for Greg Biffle. Hooters most recently sponsored the No. 9 of Chase Elliott from 2017 to 2024. Hooters has sponsored the Major League Eating-sanctioned "Hooters Worldwide Wing Eating Championship" since 2012. Hooters has also licensed its name for the Hooters Road Trip PlayStation racing game. Furthermore, Hooters licensed the Hooters Calendar for Hooters Calendar Girl, a mobile wallpaper application, and Hooters Calendar Girl Tubin', a mobile game, both by Oasys Mobile. It was also one of several real world brands that appeared in the 2011 video game Homefront.
Florey became the President of the Royal Society on 30 November 1960. Since 1873, the Royal Society had occupied Burlington House. While it had a sumptuous Meeting Room and Council Room, the administrative staff, who numbered about seventy in 1960, worked in cramped conditions in the awkward-to-access offices in the attic and basement. Florey decided to seek better accommodation. In December 1960, Florey was informed that plans to build new accommodation for the Foreign Office at Carlton House Terrace had fallen though and that the Crown Estate Commissioners had suggested that the premises might be suitable for the headquarters of cultural bodies. Florey inspected the property and lodged a formal application to occupy four houses on the site, numbers 6 to 9. Florey raised the money required to realise the architect Sir William Holford's vision for the interiors. While the government paid the rent and upkeep on the Royal Society's accommodation, about £45,000 in 1963 (equivalent to £822,000 in 2025), repairs and alterations were at the Royal Society's expense and ultimately came to around £850,000 (equivalent to £15,525,000 in 2025). The move was not completed during Florey's term of office; the new building was opened by Queen Elizabeth II on 21 November 1967. Florey pursued a more progressive and internationalist outlook for the Royal Society. He hosted Yuri Gagarin at a luncheon at Burlington House, and led Royal Society visits to Russia in 1965 and 1967.
Sources: en.wikipedia.org
=== Variations === Novolog Mix 70/30 is a product which contains 30% insulin aspart and 70% insulin aspart protamine. The insulin aspart protamine portion is a crystalline form of insulin aspart, which delays the action of the insulin, giving it a prolonged absorption profile after injection. The combination of the fast-acting form and the long-acting form allows the patient to receive fewer injections over the course of the day. Novolog Mix is marketed to be used with the Novo Nordisk Flexpen. The onset of action is less than 30 minutes, the peak action is reached in 1–4 hours, and the duration is less than 24 hours. NovoLog Mix is marketed in some countries as NovoMix 30. NovoRapid is produced in Saccharomyces cerevisiae by recombinant DNA technology. A faster acting version of aspart insulin, known as fast-aspart (Fiasp) insulin, is associated with more efficient control of post-prandial rise in blood glucose, without increasing the risks of hypoglycemia and glycemic variability.
When their bone density is low, there is a higher risk of microfractures in the vertebrae causing the spine to curve and bend. These curves and bends cause pressure onto the vertebra which could cause progression of scoliosis. When the spine is in this shape, it makes it very difficult for the children to play and exercise. This will also improve the severity of the scoliosis.
Although the war was largely treated with indifference in metropolitan France, "the dirty war" has been featured in various films, books and songs. Since its declassification in the 2000s, television documentaries have been released using new perspectives about the U.S. covert involvement and open critics about the French propaganda used during wartime. The famous Communist propagandist Roman Karmen was in charge of the media exploitation of the battle of Dien Bien Phu. In his documentary, Vietnam (Вьетнам, 1955), he staged the famous scene with the raising of the Việt Minh flag over de Castries' bunker which is similar to the one he staged over the Berlin Reichstag roof during World War II (Берлин, 1945) and the S-shaped POW column marching after the battle, where he used the same optical technique he experimented with before when he staged the German prisoners after the Siege of Leningrad (Ленинград в борьбе, 1942) and the Battle of Moscow (Разгром немецких войск под Москвой, 1942). Hollywood made a film about Dien Bien Phu in 1955, Jump into Hell, directed by David Butler and scripted by Irving Wallace, before his fame as a bestselling novelist. Hollywood also made several films about the war, Robert Florey's Rogues' Regiment (1948). Samuel Fuller's China Gate (1957). and James Clavell's Five Gates to Hell (1959). The first French movie about the war, Shock Patrol (Patrouille de Choc) aka Patrol Without Hope (Patrouille Sans Espoir) by Claude Bernard-Aubert, came out in 1956.
=== Epigenetics === p53 function is also influenced by chromatin environment. The corepressor TRIM24 restricts p53 binding to epigenetically repressed loci by recognizing methylated histones. This interaction enables p53 to interpret local chromatin context and regulate gene expression in a locus-specific manner.
Sources: en.wikipedia.org
== P == p53 - package - palindromic sequence - palmitoyl acyltransferase - Parkinson's disease - Partial cleavage stimulation factor domain - pBR322 - PCR - pedigree - peptide - peptide-transporting ATPase - peptide bond - phage - phagemid - phenotype - phenylacetaldoxime dehydratase - PhIP-Seq - phosphatase, alkaline - phosphatidylcholine 12-monooxygenase - phosphatidylcholine desaturase - phosphatidylinositol a-mannosyltransferase - phosphodiester bond - phospholipid acyltransferase - phosphonate-transporting ATPase - phosphorylation - physical map - plant calmodulin-binding domain - plasmid - plastoquinol/plastocyanin reductase - point mutation - poly-A track - polyA tail - polyacrylamide gel - polyclonal antibodies - polydactyly - polymerase - polymerase chain reaction - polymorphism - polynucleotide kinase - polypeptide - polyvinyl-alcohol dehydrogenase (acceptor) - positional cloning - positional sequencing - post-transcriptional regulation - post-translational modification - post-translational processing - post-translational regulation - PRE - precursor mRNA - primary immunodeficiency - primary transcript - primer - primer extension - probe - processivity - progesterone 5alpha-reductase - promoter - pronucleus - prostate cancer - protease - proteasome - proteasome ATPase - protein - Protein translocation - proto-oncogene - pseudobaptigenin synthase - pseudogene - pseudoknot - pseudorevertant - pulse sequence database - pulsed field gel electrophoresis - purine - PyrC leader - PyrD leader - pyrimidine
=== Discontinued === 1-Amino-5-bromouracil (ABU) – undefined mechanism of action [60] ABT-418 – nicotinic acetylcholine receptor agonist [61] ABT-436 – vasopressin V1B receptor antagonist [62] Adipiplon (NG-273) – GABAA receptor positive allosteric modulator and nonbenzodiazepine [63] Alnespirone (S-20499) – serotonin 5-HT1A receptor agonist [64] Alosetron (GR-68755; GR-68755C; Lotronex) – serotonin 5-HT3 receptor antagonist [65] Alpidem (Ananxyl; S-800342-001; SL-800342) – GABAA receptor positive allosteric modulator and nonbenzodiazepine/imidazopyridine [66] Alprazolam lingual spray – GABAA receptor positive allosteric modulator and benzodiazepine [67] AN-788 (IP-2018; NSD788) – serotonin–dopamine reuptake inhibitor (SDRI) [68] AP-521 – serotonin 5-HT1A receptor partial agonist [69] Aprepitant (Emend; L-754030; MK-0869; MK-869; ONO-7436) – neurokinin NK1 receptor antagonist [70] AVN-211 (CD-008-0173) – serotonin 5-HT6 receptor antagonist [71] AVN-397 – undefined mechanism of action [72] AZD-2327 – δ-opioid receptor (DOR) agonist [73] AZD-8129 (AR-A000002; AR-A2XX; AR-A2) – serotonin 5-HT1B receptor antagonist [74] Befloxatone (MD-370503) – reversible inhibitor of monoamine oxidase A (RIMA) [75] Blarcamesine (AE-37; ANA001; ANAVEX 2-73) – sigma σ1 receptor agonist, muscarinic acetylcholine M1 receptor agonist, and ionotropic glutamate NMDA receptor agonist [76] Bretazenil (RO-166028) – GABAA receptor positive allosteric modulator and benzodiazepine [77] Brofaromine (Brofaremine; CGP-11305A; Consonar; Consonev) – reversible inhibitor of monoamine oxidase A (RIMA) and serotonin reuptake inhibitor (SRI) [78] Buspirone transdermal (BuSpar Patch) – serotonin 5-HT1A receptor partial agonist and other actions [79] CGS-12066 – serotonin 5-HT1B receptor partial agonist and other actions [80] Coluracetam (BCI-540; MKC-231) – ionotropic glutamate AMPA receptor positive allosteric modulator, choline uptake and acetylcholine synthesis enhancer, and racetam [81] DAA-1097 – translocator protein (TSPO) agonist [82] Devazepide (Devacade; L-364718; MK-329) – Cholecystokinin A (CCKA) receptor antagonist [83] Dipraglurant (ADX-48621; mGluR5-NAM) – metabotropic glutamate mGlu5 receptor negative allosteric modulator [84] Eglumetad (eglumegad; LY-354740) – metabotropic glutamate mGlu2 and mGlu3 receptor agonist [85] Emapunil (AC-5216; XBD173) – translocator protein (TSPO) agonist [86] Emicerfont (GW-876008; GW876008) – corticotropin releasing factor CRF1 receptor antagonist [87] Enciprazine (D-3112; WY-48624) – serotonin 5-HT1A receptor agonist and α1-adrenergic receptor ligand [88] Eplivanserin (Ciltyri; Sliwens; SR-46349; SR-46349B; SR-46615A) – serotonin 5-HT2A receptor antagonist [89] Eptapirone (F-11440) – serotonin 5-HT1A receptor agonist [90] Esprolol ((S)-ACC-9369) – beta blocker (β-adrenergic receptor antagonist) (amoxolol prodrug) [91] Flesinoxan (DU-29373) – serotonin 5-HT1A receptor agonist [92] Gabapentin (CI-945; Gabapen; GOE-3450; Neurontin) – gabapentinoid (α2δ subunit-containing voltage-gated calcium channel ligand) [93] Girisopam (EGIS-5810; GYKI-51189) – GABAA receptor positive allosteric modulator and benzodiazepine [94] GT-2203 – histamine H3 receptor agonist [95] Guanfacine (Guanfacine Carrier Wave project; SPD-554) – α2-adrenergic receptor agonist [96] Ipsapirone (BAY-Q-7821; TVX-Q-7821) – serotonin 5-HT1A receptor partial agonist [97] Isamoltane (CGP-361A) – beta blocker (β-adrenergic receptor antagonist) and serotonin 5-HT1A and 5-HT1B receptor antagonist [98] Itasetron (DAU-6215; U-98079) – serotonin 5-HT3 receptor antagonist [99] ITI-333 – serotonin 5-HT2A receptor antagonist, dopamine D1 receptor antagonist, α1A-adrenergic receptor antagonist, and μ-opioid receptor (MOR) partial agonist [100] JNJ-19567470 (CRA-5626; R-317573) – corticotropin releasing factor CRF1 receptor antagonist [101] Levetiracetam (Keppra; L-059; SIB-S1; UCB-059; UCB-22059; UCB-L059) – synaptic vesicle glycoprotein 2A (SV2A) ligand [102] Lorazepam intranasal – GABAA receptor positive allosteric modulator and benzodiazepine [103] Mavoglurant (AFQ-056; STP-7) – metabotropic glutamate mGlu5 receptor antagonist [104] Midazolam intranasal (ITI-111; midazolam nasal spray; Nayzilam; USL-261) – GABAA receptor positive allosteric modulator and benzodiazepine [105] MK-0777 (L-830982; TPA-023) – GABAA receptor positive allosteric modulator and nonbenzodiazepine/triazolopyridazine [106] NBI-34041 (SB-723620) – corticotropin-releasing hormone (CRH) inhibitor [107] Nerisopam (EGIS-6775; GYKI-52322) – GABAA receptor positive allosteric modulator and benzodiazepine [108] Nivasorexant (ACT-539313; SORA) – orexin OX1 receptor antagonist [109] NS-11821 (NS11821) – GABAA receptor positive allosteric modulator and nonbenzodiazepine [110] Orvepitant (GW-823296; GW823296X) – neurokinin NK1 receptor antagonist [111] Osanetant (ACER-801; SR-142801; SR-142806) – neurokinin NK3 receptor antagonist [112] Panadiplon (FD-10571; FG-10571; NNC-140571; U-78875) – GABAA receptor positive allosteric modulator and nonbenzodiazepine/pyrazolopyrimidine [113] Pazinaclone (A-77000; DN-2327) – GABAA receptor positive allosteric modulator and nonbenzodiazepine/cyclopyrrolone [114] Pozanicline (A-87089.0; ABT-089) – nicotinic acetylcholine receptor agonist [115] Psilocybin (CYB-001; INT0052/2020) – non-selective serotonin receptor agonist and psychedelic hallucinogen [116] Research programme: depression and anxiety therapies - Roche/Vernalis – undefined mechanism of action [117] Research programme: GPCR modulators - Nxera Pharma – various actions [118] Research programme: monoamine oxidase A inhibitors - CeNeRx BioPharma – monoamine oxidase A (MAO-A) inhibitors [119] Ritanserin (R-55667) – serotonin 5-HT2 receptor antagonist and other actions [120] Robalzotan (AZD-7371; NAD-299) – serotonin 5-HT1A receptor antagonist [121] RS-127445 (MT-500) – serotonin 5-HT2B receptor antagonist [122] SAX-187 (WAY-181187) – serotonin 5-HT6 receptor agonist [123] Sergolexole (LY-281067) – serotonin 5-HT2 receptor antagonist [124] Siramesine (LU-28179) – sigma σ2 receptor agonist [125] SKL-PSY (FZ-016) – serotonin 5-HT1A receptor agonist [126] SSR-241586 (SSR241586) – neurokinin NK2 and NK3 receptor antagonist [127] SUN-8399 – serotonin 5-HT1A receptor agonist [128] Suriclone (RP-31264) – GABAA receptor positive allosteric modulator and nonbenzodiazepine/cyclopyrrolone [129] Talaglumetad (LY-544344) – metabotropic glutamate mGlu2 and mGlu3 receptor agonist (eglumetad prodrug) [130] Tiagabine (A-70569; CEP-6671; Gabitril; NO-050328; NO-328) – GABA transporter 1 (GAT-1) blocker and GABA reuptake inhibitor Troriluzole (BHV-4157; Dazluma; FC-4157; trigriluzole) – various actions (riluzole prodrug) [131] Vestipitant (GW-597599) – neurokinin NK1 receptor antagonist [132] Zabaglurant (TMP-301; TMP301; Heptares 25; HTL-0014242; HTL14242) – metabotropic glutamate mGlu5 receptor negative allosteric modulator [133] Zalospirone (WY-47846) – serotonin 5-HT1A receptor agonist [134]
Work on the settlement began in 1843 and it became the capital in July 1845. It was named after Lord Stanley, Secretary of State for War and the Colonies at the time. In 1849, 30 married Chelsea Pensioners were settled there to help with the defence of the islands and to develop the new settlement. The settlement soon grew as a deep-water port, specialising at first in ship repairs; before the construction of the Panama Canal, Port Stanley was a major repair stop for ships travelling through the Straits of Magellan. The rough waters and intense storms found at the tip of the continent forced many ships to Stanley Harbour, and the ship repair industry helped to drive the island economy. Later it became a base for whaling and sealing in the South Atlantic and Antarctic. Later still it was an important coaling station for the Royal Navy. This led to ships based here being involved in the Battle of the Falkland Islands in the First World War, and the Battle of the River Plate in the Second World War. Landslides caused by excessive peat cutting destroyed part of the town in 1879 and again in 1886, which killed two people. At about midnight on 29 November 1878 a black moving mass, several feet high, was moving forwards at a rate of 4 miles per hour (6.4 km/h) or 5 miles per hour (8.0 km/h). The next morning the town was cut in two; the only way to travel between the two parts was by boat. During the Second World War, a hulk in Stanley Harbour was used for interning the British Fascist and Mosleyite Jeffrey Hamm.
Sources: en.wikipedia.org
Dry lyophilized powder tolerates short ambient exposure during handling and shipping. Long-term room-temperature storage is not recommended because moisture uptake and slow degradation can occur over months. Storage at minus twenty degrees Celsius is the common practice for extended periods.
Typical entries list appearance, identity by mass spectrometry, purity by chromatography, water or moisture content, and residual counter-ion. Some certificates also report microbial limits and endotoxin for materials intended for laboratory use. The reported methods and acceptance ranges vary between suppliers.
The peptide is often supplied as an acetate or trifluoroacetate salt, and the counter-ion affects solubility, weight-per-mole calculations, and compatibility with cell assays. Trifluoroacetate can be undesirable in some biological experiments. Knowing the salt form is necessary for accurate concentration determination.
Reconstituted solutions are typically kept refrigerated at two to eight degrees Celsius when used within a short window, or frozen in aliquots for longer periods. Repeated freeze-thaw cycles are avoided because they can reduce recovery of intact peptide.